KBC Group
ELVN icon

KBC Group’s Enliven Therapeutics ELVN Stock Holding History

KBC Group’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$92K Buy
1,805
+847
+88% +$36K ﹤0.01% 1468
2026
Q1 		$38K Buy
+958
New +$26.5K ﹤0.01% 1738

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

KBC Group's ELVN Position: Q2 2026 in Review

KBC Group increased its Enliven Therapeutics (ELVN) stake by 88% in Q2 2026, buying an estimated $36K and bringing the position to 1,805 shares worth $92K. The position accounts for ﹤0.01% of the portfolio, ranked #1468.

KBC Group first reported a position in ELVN in Q1 2026 and has held it in 2 quarters since. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • KBC Group held 1,805 shares of Enliven Therapeutics worth $92K as of Q2 2026.
  • KBC Group bought 847 Enliven Therapeutics shares in Q2 2026, an estimated $36K.
  • Enliven Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1468 holding.
  • KBC Group first reported a position in Enliven Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.